Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH4 | P08319 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7979579 | 0.98 | TRPA1 (0.54) | TRPA1TRPV1NAAAOPRM1SPHK1 | |
| SCHEMBL8739301 | 0.98 | TRPA1 (0.54) | TRPA1TRPV1NAAAOPRM1SPHK1 | |
| SCHEMBL11422618 | 0.93 | — | — | |
| SCHEMBL8763286 | 0.85 | TRPA1 (0.59) | TRPA1TRPV1 | |
| SCHEMBL1021266 | 0.83 | — | — | |
| SCHEMBL9282879 | 0.83 | — | — | |
| SCHEMBL30350978 | 0.80 | TRPA1 (0.65) | TRPA1TRPV1 | |
| SCHEMBL483526 | 0.79 | NAAA (0.43) | TRPA1TRPV1NAAAOPRM1LMNA | |
| SCHEMBL6892191 | 0.79 | TRPA1 (0.52) | TRPA1TRPV1LMNA | |
| SCHEMBL6577575 | 0.77 | NAAA (0.46) | TRPA1TRPV1NAAAOPRM1SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107556450-B | Dynamic polymer with hybrid cross-linked network and application thereof | 翁秋梅 | 2020-11-24 | — | — | CN | disclosed |
| CN-109666120-A | A kind of energy-absorbing method based on hydridization dynamic aggregation object | 翁秋梅 | 2019-04-23 | — | — | CN | disclosed |
| CN-107556450-A | A kind of dynamic aggregation thing and application with hybrid cross-linked network | 翁秋梅 | 2018-01-09 | — | — | CN | disclosed |
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1446110-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | Structural Bioinformatics Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003032916-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | STRUCTURAL BIOINFORMATICS INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| US-6225310-B1 | Fused 1,2,4-thiadiazine derivatives, their preparation and use | NOVO NORDISK A/S (DK) | 2001-05-01 | — | — | US | disclosed |
| EP-1000066-A1 | FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999003861-A1 | FUSED 1,2,4-THIADIAZINE DERIVATIVES, THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1999-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | TRPA1 3115/4885TRPV1 3569/4885NAAA 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.